Latest Expert Exchange Queries
sitemapHome | Registration | Job Portal for CA's | Expert Exchange | Currency Converter | Post Matrimonial Ads | Post Property Ads
 
 
News shortcuts: From the Courts | News Headlines | VAT (Value Added Tax) | Service Tax | Sales Tax | Placements & Empanelment | Various Acts & Rules | Latest Circulars | New Forms | Forex | Auditing | Direct Tax | Customs and Excise | ICAI | Corporate Law | Markets | Students | General | Indirect Tax | Mergers and Acquisitions | Continuing Prof. Edu. | Budget Extravaganza | Transfer Pricing
 
 
 
 
Popular Search: ARTICLES ON INPUT TAX CREDIT IN VAT :: ACCOUNTING STANDARD :: VAT Audit :: ACCOUNTING STANDARDS :: cpt :: VAT RATES :: due date for vat payment :: Central Excise rule to resale the machines to a new company :: ICAI offer Get Windows 7,Office 2010 in Rs.799 Taxes :: form 3cd :: empanelment :: list of goods taxed at 4% :: articles on VAT and GST in India :: TAX RATES - GOODS TAXABLE @ 4% :: TDS
 
 
« News Headlines »
 Is government tapping your phone?
 Income tax department to use analytics to look for discrepancies in bank accounts
 GST Council fails to break deadlock over indirect tax regime, next meet on Dec 11 and 12 to hammer out differences
 Invoking Writ Jurisdiction For Income Tax Matters
 How to file income-tax returns online
 How Income Tax Returns Are Scrutinised
 All About New Income Disclosure Scheme to make Demonetisation successful
 Your deposit may draw income tax notice
 Accepting payment under IDS 2016
 New disclosure scheme could see 50% tax and 4-year limit on cash use for unaccounted deposits
 Pay 50% tax on unaccounted deposits, or 85% if caught, says Modi government

Dr Reddys net declines 52% on back of forex losses, one-off tax
October, 24th 2008

The countrys second largest pharma firm Dr Reddys Laboratories Ltd posted a 52% fall in net profit for the quarter to 30 September than a year earlier, due to foreign exchange losses and a one-off tax at its German subsidiary.

Net profit for the quarter stood at Rs121 crore, or 8% of the companys revenues, compared with Rs252.70 crore, or 20% of the revenues in the year-ago period.

Our revenue growth is on track with the whole-year guidance of 25% in rupee terms, said chief executive G.V. Prasad. The drug maker, he added, was experiencing margin pressures due to higher costs of buying raw material from China, besides high oil prices.
In a filing to the Bombay Stock Exchange (BSE), the company said its consolidated net profit for the quarter declined by 21.62% to Rs86.60 crore, over the same period a year ago. Company officials clarified this figure was arrived at by using the Indian system of accounting. Dr Reddys has now shifted to accounting based on the International Financial Reporting Standard, the first Indian drug manufacturer to do so.

The company paid Rs109.90 crore tax in the quarter, due to a change in tax laws in Germany where its subsidiary Betapharm Arzneimittel GmbH is located. Chief financial officer Saumen Chakraborty said if the one-off tax was discounted, the firms net profit grew by 19% in the September quarter.

Another factor dragging the firms profitability was foreign exchange losses of Rs29.60 crore in the reported quarter, against a net gain of Rs25.90 crore in foreign exchange a year earlier. Chakraborty said as on date, the company has hedged $150 million (Rs747 crore today) at Rs42 to a dollar and another $60 million at Rs47 to a dollar. The rupee fell to a record 49.81 to a dollar on Thursday.

Total revenues for the second quarter grew 30% to Rs1,620 crore, from Rs1,250 crore in the same period last year. Contributing to the companys revenue growth was increased global generic drug sales of Rs1,120 crore, up from Rs800 crore last year. Sales of generic formulations rose by 40% over the September quarter last fiscal, aided by increased volumes in North America, Russia and Germany. Generic drugs contribute nearly 70% to Dr Reddys revenue.

In the North American market, sales grew by 54% and it expects a further rise from the sale of authorized generic sumatriptan, which is expected to be launched towards the end of next quarter. Dr Reddys sells at least 40 products in the North American market.

In India, the companys sales grew at a sluggish pace of 9% because of supply side issues, Prasad said. Chief operating officer Satish Reddy said the company expected sales to slow down in other emerging markets as well due to the slower GDP growth.
Dr Reddys has also decided to amalgamate its wholly owned subsidiary Perlecan Pharma Pvt. Ltd with itself.
For Indian pharma companies, growth will moderate in the near term due to violent fluctuations in oil prices and currency. However, a lot of that will depend on what hedging strategies companies have adopted, said Hitesh Gajaria of audit and consultancy firm KPMG.

The companys shares fell 2.71%, or Rs13, on Thursday, to close at Rs466.55 on BSE.

 
 
Home | About Us | Terms and Conditions | Contact Us
Copyright 2016 CAinINDIA All Right Reserved.
Designed and Developed by Binarysoft Technologies Pvt. Ltd.
Internet Marketing Website Marketing Internet Promotion Internet Marketing India Website Marketing India Internet Promotion India Internet Marketing Consultancy Website Marketing Consulta

Transfer Pricing | International Taxation | Business Consulting | Corporate Compliance and Consulting | Assurance and Risk Advisory | Indirect Taxes | Direct Taxes | Transaction Advisory | Regular Compliance and Reporting | Tax Assessments | International Taxation Advisory | Capital Structuring | Withholding tax advisory | Expatriate Tax Reporting | Litigation | Badges | Club Badges | Seals | Military Insignias | Emblems | Family Crest | Software Development India | Software Development Company | SEO Company | Web Application Development | MLM Software | MLM Solutions